 |
| effox (Rest Of Pamphlet) |
alcohol may potentiate the hypotensive
effect of effox. This might also occur with neuroleptics and tricydic
antidepressants. A blood pressure lowering effect of effox will be increased,
if used together with phosphodiesterase inhibitors (e.g. sildenafil) which is
used for erectile dysfunction (see special warnings and contra-indications).
This might lead to life-threatening cardiovascular complications. Patients who
are on effox therapy therefore must not use phosphodiesterase inhibitors (e.g.
sildenafil)
Reports suggest, that, when administered concomitantly, effox may increase the blood level of dihydroergotamine and its hypertensive effect.
Effox may affect the patient’s reactivity to an extent that her/his ability to drive or to operate machines is impaired.
This effect is increased in combination with alcohol.
Undesirable effects:
A very common (>10% of patients) adverse reaction to effox is headache. The incidence of headache diminishes gradually with time and continued use.
At the Start of therapy or when the dosage is increased, hypotension and/or light-headedness on standing are observed commonly (i.e. in 1- 10% of patients). These symptoms may be associated with dizziness, drowsiness, reflex tachycardia, and a feeling of weakness.
Reports suggest, that, when administered concomitantly, effox may increase the blood level of dihydroergotamine and its hypertensive effect.
Effox may affect the patient’s reactivity to an extent that her/his ability to drive or to operate machines is impaired.
This effect is increased in combination with alcohol.
Undesirable effects:
A very common (>10% of patients) adverse reaction to effox is headache. The incidence of headache diminishes gradually with time and continued use.
At the Start of therapy or when the dosage is increased, hypotension and/or light-headedness on standing are observed commonly (i.e. in 1- 10% of patients). These symptoms may be associated with dizziness, drowsiness, reflex tachycardia, and a feeling of weakness.
Uncommonly (i.e. in less than 1% of patients),
nausea, vomiting, flush and allergic skin reaction (e.g. rash), which may be
sometimes severe may uncommonly occur. In single cases exfoliative dermatitis
may occur. Very rare Stevens JohnsonSyndrom may occur. Angioedema is observed
in very rare cases. Severe hypotensive responses have been reported for organic
nitrates and include nausea, vomiting, restlessness, pallor and excessive
perspiration. Uncommonly collapse may occur (sometimes accompanied by bradyarrhythmia
and syncope).Uncommonly severe hypotension may lead to enhanced angina
symptoms.
A few reports on heartburn most likely due to a nitrate-induced sphincter relaxation have been recorded.
During the treatment with effox, a temporary hypoxemia may occur due to a relative redistribution of the blood flow in hypoventilated alveolar areas. Particularly in patients with coronary artery disease this may lead to a myocardial hypoxia.
Medicine should be kept out of the reach of children
Room temperature not to exceed
30 C
Package size and presentation:
Boxes of 20 tablets
A few reports on heartburn most likely due to a nitrate-induced sphincter relaxation have been recorded.
During the treatment with effox, a temporary hypoxemia may occur due to a relative redistribution of the blood flow in hypoventilated alveolar areas. Particularly in patients with coronary artery disease this may lead to a myocardial hypoxia.
Medicine should be kept out of the reach of children
Room temperature not to exceed
30 C
Package size and presentation:
Boxes of 20 tablets
M.INAPHARM,
Under licence of
SCHWARZ
PHARMA dNAPHARN
Under licence of
SCHWARZ
PHARMA dNAPHARN
Comments
Post a Comment